Researchers reported that atypical hemolytic uremic syndrome (aHUS) is driven by abnormal activation of the alternative complement pathway, an immune response that’s independent of antibody activity, according to a study using endothelial cells that line blood vessels. These results challenge a recent report suggesting that aHUS…
Treatment with Ultomiris (ravulizumab) led to both rapid and long-lasting improvements in people with atypical hemolytic uremic syndrome (aHUS), according to a real-world study. The study found that most people who had never received a C5-inhibitor therapy before saw key blood and kidney measures return to normal. These…
Becoming educated and informed about aHUS is a good first step. Here you’ll find general information about the disease, including diagnosis, symptoms, and causes.
It helps to know others have been where you are now. Here’s a collection of our columnist’s words of wisdom to help you along on your aHUS journey.
There is no cure for aHUS yet, but here you can find more information about current therapeutic approaches, as well as experimental treatments that are in the pipeline.
Get regular updates to your inbox.
